4/A: Director's Net Exercise of Nuo Therapeutics Options

Nuo Therapeutics director C. Eric Winzer completed a net exercise of stock options, acquiring 92,654 shares of common stock.

Summary

• Director C. Eric Winzer exercised 120,313 stock options at an exercise price of $0.4 per share.
• The transaction resulted in a net acquisition of 92,654 shares of Nuo Therapeutics common stock.
• The issuer withheld 27,659 shares, valued at the closing price of $1.74 per share, to cover the exercise price.
• Following these transactions, Winzer directly owns 117,654 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director increased their direct ownership in the company through an option exercise, indicating confidence. The transaction itself is routine for equity compensation.

Positives

• Director C. Eric Winzer increased direct ownership in Nuo Therapeutics by 92,654 shares, signaling confidence in the company.
• The exercise price of $0.4 is significantly lower than the $1.74 closing price used for withholding, indicating the options were in-the-money.

Negatives

• The withholding of 27,659 shares by the issuer to cover the exercise price represents a reduction in the total shares that could have been acquired by the director.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This Form 4/A filing details an insider transaction, which is a routine disclosure for publicly traded companies. It reflects an individual director's equity compensation activity rather than broader industry trends or competitive positioning.

Comparison to Industry Standards

• This filing reports a standard insider transaction (stock option exercise and net settlement) and does not provide data for comparison to specific industry benchmarks, comparable companies, or project results. Such transactions are common mechanisms for executive compensation and equity ownership.

Stakeholder Impact

• Shareholders: Increased director ownership may be viewed positively as a sign of alignment with shareholder interests.
• Employees: No direct impact on employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• This filing does not mention any specific future actions, events, or milestones.

Key Dates

Recommendation

The filing reports a routine insider transaction where a director exercised stock options and increased their direct ownership. While this indicates confidence, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Nuo Therapeutics, AURX, SEC Form 4/A, Insider Trading, Stock Options, Director Stock Ownership, Equity Compensation, Net Exercise